Grab your ticket

About

Florian Wurm

Prof. emeritus, Dr. rer. nat. Florian Wurm

ExcellGene SA Monthey, Valais, Switzerland Swiss Federal
Institute of Technology Lausanne (EPFL),
Life Science Faculty, Lausanne

Switzerland

Florian M. Wurm, trained as Biologist/Molecular Geneticist (University of Giessen, PhD 1980). His career involved academic and industrial work: Behringwerke AG, Marburg (1981-1984), Harvard
Medical School, Boston (1984-1985), Genentech Inc, San Francisco (1986-1995), Swiss Federal Institute of Technology, Lausanne (EPFL), (1995-2015), ExcellGene SA, Monthey, Switzerland (2001-today). He contributed to the generation of several high-value therapeutic products (cumulatively now sold for multibillion Dollars/year globally). His research activities covered Process Sciences, from DNA to large-scale manufacturing, using recombinant animal cells (CHO, HEK and others) in bioreactors. He is/was founder (2001), CSO (2002-today, CEO (2015-2016) and CSO/Chairman (since 2017) of ExcellGene SA, a familyowned service company for the Pharmaceutical Industry. He retired from the EPFL in 2015. Florian is member and was Chairman of the European Society of Animal Cell Technology (ESACT). He has published, with co-workers, more than 230 highly referenced papers and filed more than 30 patents covering aspects of expression and manufacture of clinical proteins using mammalian cells in bioreactors

Joeri Kint

Dr. Joeri Kint

ExcellGene SA Monthey, Valais

Switzerland

Joeri Kint was trained in Biotechnology and BioProcess Development (University in Wageningen, MSc 2006). During his career at Intervet International B.V. (2006-2009) and Merck Animal Health (2009-2016) he contributed to the development of several veterinary vaccines for viral diseases such as coronavirus and Influenza. His PhD work (2010-2015) focused on the development of cell lines for the production of these vaccines, which are produced using embryonated chicken eggs. In 2016 he moved to Biotype GmbH, Dresden, Germany. Here he set-up a novel department for contract development and production of In Vitro Diagnostic tests for oncology and infectious diseases. Since 2020 he is Head of Business Development at ExcellGene SA, Monthey, Switzerland where he is responsible for the entire business in EU and Asia-Pacific, including all COVID-related product-development programs.